Answers are grounded in this paper and cite their sources.
PEOPLE, PLACES, AND THINGS The sun-drenched landscape of Rancho Mirage, California, provided the perfect backdrop for the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Winter Meeting, held from February 26th to March 1st, 2025. This year's gathering drew 626 attendees from the United States and abroad. President J. Quentin Clemens (University of Michigan) and his program committee deserve immense credit for crafting an exceptional and diverse scientific program. The breadth of topics covered was truly impressive, reflecting the multifaceted nature of the society, offering valuable information for everyone in attendance. The meeting commenced Wednesday with the basic science session which included a keynote lecture entitled “Molecular Profiling of the Neurogenic Bladder: What are the data telling us?” presented by Dr Rosalyn Adam, PhD, from Boston Children's Hospital. After the basic science session was the annual Fellows Forum in the afternoon. This intimate session offered a unique platform for fellows to network, present their research, and gain invaluable insights into navigating their careers. The emphasis on mentorship and professional development underscored SUFU's commitment to nurturing the next generation of leaders in the field. This commitment to the next generation was further evident by the complement of medical students and residents in attendance to present their work. The society provided travel scholarships to 14 residents to cover expenses related to the meeting to alleviate any financial restrictions to their attendance (Figure 1).Figure 1.: President J Quentin Clemens and some of the residents who were awarded the SUFU travel award to offset the costs associated with travel to the meeting. SUFU, Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction.On Thursday, Friday, and Saturday, attendees were presented the opportunity to learn about various clinically relevant topics through research presentations, video sessions, panel discussions, etc. The presentations were consistently insightful, sparking lively discussions and fostering a collaborative atmosphere. Panel discussions were wide ranging with experts presenting on topics such as “The Cutting Edge of Pelvic Medicine-The Latest Advances,” “Advances in Treatment of Menopause, Perimenopause, and GSM,” and “Point-Counterpoint, 65 year old male with OAB and a prostate, prostate surgery or sacral neuromodulation?” (Figure 2).Figure 2.: A panel discussion regarding “The Cutting Edge of Pelvic Medicine-The Most Recent Developments.” Howard Goldman (Cleveland Clinic) moderated the discussion on the following topics: Electrical AUS (Benoit Peyronnet, Rennes University), Newest Tech in ITNS (Kenneth Peters, Corewell Health), Aquablation (Kevin Zorn, Steinberg Urology), Urinary tract infection Vaccine (A Lenore Ackerman, University of California Los Angeles), and Proact (Bahaa Malaeb, University of Michigan).Outside of conference hours, many attendees used their time to reconnect with colleagues and former trainees/mentors. Many of the fellowship programs held alumni events during the meeting offering a way for current trainees to connect with former trainees who have since dispersed throughout the United States and beyond (Figure 3).Figure 3.: Alumni reception hosted by Cleveland Clinic.The meeting adjourned just afternoon on Saturday presenting the dilemma of whether to use the remainder of the weekend to travel back home or to soak up as much of the Rancho Mirage sunshine as possible (Figure 4). Overall, the meeting was a great success and set the stage for upcoming meetings within the society. Over the next year, SUFU will again meet on April 26 at the annual AUA meeting in Las Vegas and will host their annual resident preceptorship in Chicago August 21 to 23. More information regarding these upcoming meetings can be found on SUFU's website.Figure 4.: Places: Take me to the desert! The 2025 SUFU winter meeting took place at the Westin Rancho Mirage Golf Resort and Spa. SUFU, Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction.MARCH 2025 JUOP ARTICLES Health Services Research In the post-COVID era, telemedicine is certainly an ongoing part of medical practice because physicians and patients continue to refine when to use it over a traditional in person visit. Gul et al1 performed a qualitative designed study using patients with urologic cancers. The key messages from the abstract were that (1) convenience is the primary benefit, (2) appropriateness is a concern based on visit goals, and (3) there are possible impacts on care quality. For those new to qualitative research, a common unique term in this space is thematic saturation, which is the idea that after X number of patient interviews you start hearing the same topics. Often saturation occurs after 12 patients, and this was pointed out in peer review. This group looked at 40 with the idea of determining if cancer subtype mattered, and the finding was that it did not. Rural patients placed a higher value on future telemedicine. The lack of a physical examination is discussed and relates to concerns with using telemedicine for a new patient visit. As a personal note, I find telemedicine a fantastic option for follow-up visits to discuss testing results and finalize treatment plans. I avoid new patient visits, but agree that the overall impact of telemedicine may reduce urban-rural health care disparities and should be a future area of study and refinement. See also—further editorial comments from Goradia and Sood.2 Goldman et al3 used a large commercial and Medicare claims database to look at the use of MRI prebiopsy for prostate cancer detection. Although level 1 evidence exists, guidelines still do not emphatically state that all biopsies should have MRI staging first, and lack of access is often cited as a factor. Nevertheless, MRI use has increased substantially from 2.7% to 30% in this study, and to 59% in prior biopsy cases. MRI was associated with higher treatment rates, and more utilized in urban areas. The limitations include a lack of pathology variables, but the strengths include large numbers of both commercially insured and Medicare patients. From my experience with guidelines panel discussions, this topic is fascinating as to whether the recommendations should only consider the science, vs include practical considerations of access and high quality providers. See also—excellent editorial from Marks.4 On the topic of transurethral resection of bladder tumors, Nasrallah et al5 contribute a health services research look at blue light cystoscopy. This technology has been around since the 1990s and well-studied, including randomized methods that support benefits in tumor identification and recurrence rates. However, downstream metrics such as progression and definitive treatment remain mixed and utilization seems limited to academic centers with higher volume bladder cancer referrals.6 This study uses a Veterans health care database with nonrandomized but propensity-weighted methods to also show lower recurrence rates (38% decrease) but no difference in progression rates or cystectomy conversions. The population was high-risk nonmuscle invasive, but they had a small number of progressions to analyze. These conflicting results need resolution and may explain widely different practice patterns at my institution and others. See also—editorial comments from Aliaga and Fernandez from Chile.7 RARE CONDITIONS MacDonald et al8 performed a retrospective review at a single, tertiary cancer center of 35 patients (1993-2024) with primary urethral adenocarcinoma. This paper, and the peer review comments and revisions, are a common reflection of the challenges in rare oncology conditions, with the central theme being heterogeneity of disease stage and treatment with small sample sizes. The heterogeneity drives a small sample size of patients into multiple smaller comparisons based on patient demographics, histologic subtypes, presenting stage, and treatment plans. The reviewers did a nice job helping the authors focus on a few key findings, and the results were (1) histology—primary urethral adenocarcinoma is only 10% to 16% of the rare whole of primary urethral carcinoma, and has clear cell and nonclear cell adenocarcinoma variants, (2) presentation is majority advanced stage and often includes radical cystectomy, (3) neoadjuvant chemotherapy (cisplatin based) and radiation have been attempted but without clear evidence of downstaging (distinct from bladder adenocarcinoma), and (4) survival is poor with < 50% overall survival at 5 years, and nonclear cell adenocarcinoma being distinctly worse. Future efforts need to identify better neoadjuvant strategies and to pool larger numbers of patients to compare surgical extirpation vs radiation.
No takes yet. Share an insight, caveat, or question.
Trump et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: